Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 629-661-9 | CAS number: 83834-59-7
Ethylhexyl Methoxycinnamate, an UV-B absorber used in sunscreens was orally administered to rats (12/sex/group) at the doses 0 (control), 200, 450 and 1000 mg/kg/day, 7 days per week for at least 13 weeks. At the termination of the treatment, half of the controls and of the high-dose rats were allowed 5 additionally weeks on normal diet prior to sacrifice.
Body weight, feed consumption and signs of toxicity were recorded weekly. Ophthalmoscopy and urine analysis were performed twice during the study. Blood chemical and hematological investigations were carried out at the beginning, during and at the end of the treatment period. An additional blood chemical investigation was performed after the recovery period. Post mortem investigations comprised full autopsy, organ weight determinations and histological examination.
The feed intake and the body weight development of treated animals were similar to those of controls. No symptoms indicative of pathologic conditions, ophthalmological abnormalities or mortalities as consequence of the treatment with the test compound were recorded during the study. Laboratory investigations in high-dose females (1000 mg/kg/day) revealed an increase of the plasma activity of GLDH which was reversed after the recovery period. The absolute as well as the allometrically adjusted weights of the kidneys were slightly increased in males of the high-dose group. No deviations of the weights were found after the recovery period, thus indicating an adaptive change. The glycogen content of the livers in high-dose animals was reduced and in 5 of 12 animals it was accompanied by slight shrinkage of the hepatocytes. In females of mid and high-dose group the amount of the iron positive material phagocytized by Kupffer cells was slightly increased. These conditions were reversed after the recovery period.
There was no obvious effect related to the treatment, which was detectable by the hematological, blood chemical and urine parameters at the mid- (450 mg/kg/day) and low-dose (200 mg/kg/day) levels. A slight increase of the iron positive material phagocytized by the Kupffer cells was observed in mid-dose females.
It is concluded that the treatment with Ethylhexyl Methoxycinnamate was well tolerated at any dose level and that under the conditions of this study only minor and reversible changes occur at the doselevel of 1000 mg/kg/day, whereas the dose of 450 mg/kg/day does not induce any adverse effect in the rat. Based on these results, ethylhexyl methoxycinnamate does not need to be classified as toxic after repeated exposure based on the criteria outlined in regulation 1272/2008/EC and 67/548/EEC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again